These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 22797806)

  • 1. Attempted suicide under high dose dopaminergic therapy including apomorphine.
    Struhal W; Guger M; Hödl S; Ung SC; Bach M; Ransmayr G
    Wien Klin Wochenschr; 2012 Jul; 124(13-14):461-3. PubMed ID: 22797806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impulse control disorder-linked hypersexuality complicated by disseminated gonococcal infection in a patient with Parkinson's disease.
    Moegle C; Grillon A; Anheim M; Lipsker D; Velter C
    Rev Neurol (Paris); 2020 May; 176(4):292-293. PubMed ID: 32139181
    [No Abstract]   [Full Text] [Related]  

  • 3. [Continuous subcutaneous infusion of apomorphine in Parkinson's disease: retrospective analysis of a series of 81 patients].
    Rambour M; Moreau C; Salleron J; Devos D; Kreisler A; Mutez E; Simonin C; Annic A; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2014 Mar; 170(3):205-15. PubMed ID: 24594365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Candidate patient for subcutaneous apomorphine injection].
    Chacón JR; Mata M
    Rev Neurol; 2012; 55 Suppl 1():S7-9. PubMed ID: 23169232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Candidate patient for treatment with continuous apomorphine infusion].
    Martí MJ; Kulisevsky J
    Rev Neurol; 2012; 55 Suppl 1():S15-9. PubMed ID: 23169228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Subcutaneous continuous apomorphine infusion: treatment initiation and follow up].
    Grandas FJ; Sesar-Ignacio Á
    Rev Neurol; 2012; 55 Suppl 1():S21-4. PubMed ID: 23169229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years.
    Morgante L; Basile G; Epifanio A; Spina E; Antonini A; Stocchi F; Di Rosa E; Martino G; Marconi R; La Spina P; Nicita-Mauro V; Di Rosa AE
    Arch Gerontol Geriatr Suppl; 2004; (9):291-6. PubMed ID: 15207426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hypersexuality and other impulse control disorders in Parkinson's disease].
    Nelis EA; Berendse HW; van den Heuvel OA
    Ned Tijdschr Geneeskd; 2016; 160():A9359. PubMed ID: 26732226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease.
    Di Rosa AE; Epifanio A; Antonini A; Stocchi F; Martino G; Di Blasi L; Tetto A; Basile G; Imbesi D; La Spina P; Di Raimondo G; Morgante L
    Neurol Sci; 2003 Oct; 24(3):174-5. PubMed ID: 14598073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous subcutaneous apomorphine infusion in Parkinson's disease patients with cognitive dysfunction: A retrospective long-term follow-up study.
    Borgemeester RWK; van Laar T
    Parkinsonism Relat Disord; 2017 Dec; 45():33-38. PubMed ID: 29032012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of increasing doses of apomorphine during stereotaxic neurosurgery in Parkinson's disease: clinical score and internal globus pallidus activity. Short communication.
    Stefani A; Stanzione P; Bassi A; Mazzone P; Vangelista T; Bernardi G
    J Neural Transm (Vienna); 1997; 104(8-9):895-904. PubMed ID: 9451721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous infusion of apomorphine in patients with advanced Parkinson's disease and different degrees of functional disability.
    Salazar G; Martín J; Fragoso M; Font MA
    Neurologia; 2017; 32(6):407-410. PubMed ID: 26699210
    [No Abstract]   [Full Text] [Related]  

  • 13. DA agonists -- non-ergot derivatives: apomorphine: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S83-9. PubMed ID: 12211146
    [No Abstract]   [Full Text] [Related]  

  • 14. Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results.
    Stocchi F; Vacca L; De Pandis MF; Barbato L; Valente M; Ruggieri S
    Neurol Sci; 2001 Feb; 22(1):93-4. PubMed ID: 11487217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous apomorphine infusion in advanced idiopathic Parkinson's disease and agranulocytosis: a case report.
    Condé S; Marques A; Derost P; Debilly B; Lauxerois M; Chanson E; Durif F
    Parkinsonism Relat Disord; 2020 Sep; 78():68-69. PubMed ID: 32739839
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of apomorphine in Parkinson's disease.
    O'Sullivan JD; Lees AJ
    Hosp Med; 1999 Nov; 60(11):816-20. PubMed ID: 10707193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impulse control symptoms in patients with Parkinson's disease: The influence of dopaminergic agonist.
    Vargas AP; Vaz LS; Reuter A; Couto CM; Costa Cardoso FE
    Parkinsonism Relat Disord; 2019 Nov; 68():17-21. PubMed ID: 31621612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.
    Colzi A; Turner K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1998 May; 64(5):573-6. PubMed ID: 9598668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease.
    Factor SA
    Neurology; 2004 Mar; 62(6 Suppl 4):S12-7. PubMed ID: 15037666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apomorphine therapy in Parkinson's disease: a review.
    Haq IU; Lewitt PA; Fernandez HH
    Expert Opin Pharmacother; 2007 Nov; 8(16):2799-809. PubMed ID: 17956200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.